{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T02:03:57Z","timestamp":1785809037006,"version":"3.56.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Diagn Ther"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s40291-024-00756-4","type":"journal-article","created":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T11:16:00Z","timestamp":1731064560000},"page":"55-66","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Emerging Radiopharmaceuticals in Pet Imaging for Mesothelioma: A Review of [18F]FDG Alternatives"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9150-4367","authenticated-orcid":false,"given":"Priscilla","family":"Guglielmo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2645-5236","authenticated-orcid":false,"given":"Cinzia","family":"Crivellaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5868-3372","authenticated-orcid":false,"given":"Angelo","family":"Castello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3396-8099","authenticated-orcid":false,"given":"Carminia Maria","family":"Della Corte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5418-5168","authenticated-orcid":false,"given":"Maria","family":"Pagano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5781-7726","authenticated-orcid":false,"given":"Silvia","family":"Marchesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7169-5343","authenticated-orcid":false,"given":"Mario","family":"Occhipinti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2274-1702","authenticated-orcid":false,"given":"Paolo Andrea","family":"Zucali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5955-9488","authenticated-orcid":false,"given":"Laura","family":"Evangelista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,8]]},"reference":[{"key":"756_CR1","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/his.15106","volume":"84","author":"S Klebe","year":"2024","unstructured":"Klebe S, Judge M, Brcic L, Dacic S, Galateau-Salle F, Nicholson AG, Roggli V, Nowak AK, Cooper WA. Mesothelioma in the pleura, pericardium and peritoneum: recommendations from the international collaboration on cancer reporting ( <scp>ICCR<\/Scp> ). Histopathology. 2024;84:633\u201345. https:\/\/doi.org\/10.1111\/his.15106.","journal-title":"Histopathology"},{"key":"756_CR2","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0226-2020","volume":"30","author":"R Asciak","year":"2021","unstructured":"Asciak R, George V, Rahman NM. Update on biology and management of mesothelioma. Eur Respir Rev. 2021;30: 200226. https:\/\/doi.org\/10.1183\/16000617.0226-2020.","journal-title":"Eur Respir Rev"},{"key":"756_CR3","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.annonc.2021.11.005","volume":"33","author":"S Popat","year":"2022","unstructured":"Popat S, Baas P, Faivre-Finn C, Girard N, Nicholson AG, Nowak AK, Opitz I, Scherpereel A, Reck M. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up\u2606. Ann Oncol. 2022;33:129\u201342. https:\/\/doi.org\/10.1016\/j.annonc.2021.11.005.","journal-title":"Ann Oncol"},{"key":"756_CR4","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.21037\/tlcr.2019.11.11","volume":"9","author":"N Alpert","year":"2020","unstructured":"Alpert N, Gerwen van M, Taioli E. Epidemiology of mesothelioma in the 21st century in Europe and the United States, 40 years after restricted\/banned asbestos use. Transl Lung Cancer Res. 2020;9:S28\u201338. https:\/\/doi.org\/10.21037\/tlcr.2019.11.11.","journal-title":"Transl Lung Cancer Res"},{"key":"756_CR5","doi-asserted-by":"publisher","first-page":"E254","DOI":"10.3978\/j.issn.2072-1439.2013.11.28","volume":"5","author":"N van Zandwijk","year":"2013","unstructured":"van Zandwijk N, Clarke C, Henderson D, Musk AW, Fong K, Nowak A, Loneragan R, McCaughan B, Boyer M, Feigen M, et al. Guidelines for the Diagnosis and Treatment of Malignant Pleural Mesothelioma. J Thorac Dis. 2013;5:E254-307. https:\/\/doi.org\/10.3978\/j.issn.2072-1439.2013.11.28.","journal-title":"J Thorac Dis"},{"key":"756_CR6","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1093\/carcin\/bgz004","volume":"40","author":"M Van Gerwen","year":"2019","unstructured":"Van Gerwen M, Alpert N, Wolf A, Ohri N, Lewis E, Rosenzweig KE, Flores R, Taioli E. Prognostic factors of survival in patients with malignant pleural mesothelioma: an analysis of the National Cancer Database. Carcinogenesis. 2019;40:529\u201336. https:\/\/doi.org\/10.1093\/carcin\/bgz004.","journal-title":"Carcinogenesis"},{"key":"756_CR7","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","volume":"397","author":"P Baas","year":"2021","unstructured":"Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, Mansfield AS, Popat S, Jahan T, Antonia S, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397:375\u201386. https:\/\/doi.org\/10.1016\/S0140-6736(20)32714-8.","journal-title":"Lancet"},{"key":"756_CR8","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1038\/s41591-021-01541-0","volume":"27","author":"PM Forde","year":"2021","unstructured":"Forde PM, Anagnostou V, Sun Z, Dahlberg SE, Kindler HL, Niknafs N, Purcell T, Santana-Davila R, Dudek AZ, Borghaei H, et al. Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial. Nat Med. 2021;27:1910\u201320. https:\/\/doi.org\/10.1038\/s41591-021-01541-0.","journal-title":"Nat Med"},{"key":"756_CR9","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1002\/cncr.23034","volume":"110","author":"L Greillier","year":"2007","unstructured":"Greillier L, Cavailles A, Fraticelli A, Scherpereel A, Barlesi F, Tassi G, Thomas P, Astoul P. Accuracy of pleural biopsy using thoracoscopy for the diagnosis of histologic subtype in patients with malignant pleural mesothelioma. Cancer. 2007;110:2248\u201352. https:\/\/doi.org\/10.1002\/cncr.23034.","journal-title":"Cancer"},{"key":"756_CR10","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1016\/S0140-6736(03)13079-6","volume":"361","author":"N Maskell","year":"2003","unstructured":"Maskell N, Gleeson F, Davies R. Standard pleural biopsy versus CT-guided cutting-needle biopsy for diagnosis of malignant disease in pleural effusions: a randomised controlled trial. Lancet. 2003;361:1326\u201330. https:\/\/doi.org\/10.1016\/S0140-6736(03)13079-6.","journal-title":"Lancet"},{"key":"756_CR11","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1016\/j.chest.2022.11.019","volume":"163","author":"A Sundaralingam","year":"2023","unstructured":"Sundaralingam A, Aujayeb A, Akca B, Tiedeman C, George V, Carling M, Brown J, Banka R, Addala D, Bedawi EO, et al. Achieving molecular profiling in pleural biopsies. Chest. 2023;163:1328\u201339. https:\/\/doi.org\/10.1016\/j.chest.2022.11.019.","journal-title":"Chest"},{"key":"756_CR12","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.lungcan.2016.11.010","volume":"103","author":"S Tsim","year":"2017","unstructured":"Tsim S, Stobo DB, Alexander L, Kelly C, Blyth KG. The diagnostic performance of routinely acquired and reported computed tomography imaging in patients presenting with suspected pleural malignancy. Lung Cancer. 2017;103:38\u201343. https:\/\/doi.org\/10.1016\/j.lungcan.2016.11.010.","journal-title":"Lung Cancer"},{"key":"756_CR13","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.jtho.2022.11.018","volume":"18","author":"SI Katz","year":"2023","unstructured":"Katz SI, Straus CM, Roshkovan L, Blyth KG, Frauenfelder T, Gill RR, Lalezari F, Erasmus J, Nowak AK, Gerbaudo VH, et al. Considerations for imaging of malignant pleural mesothelioma: a consensus statement from the International Mesothelioma Interest Group. J Thorac Oncol. 2023;18:278\u201398. https:\/\/doi.org\/10.1016\/j.jtho.2022.11.018.","journal-title":"J Thorac Oncol"},{"key":"756_CR14","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.2214\/ajr.172.4.10587144","volume":"172","author":"RT Heelan","year":"1999","unstructured":"Heelan RT, Rusch VW, Begg CB, Panicek DM, Caravelli JF, Eisen C. Staging of malignant pleural mesothelioma: comparison of CT and MR imaging. Am J Roentgenol. 1999;172:1039\u201347. https:\/\/doi.org\/10.2214\/ajr.172.4.10587144.","journal-title":"Am J Roentgenol"},{"key":"756_CR15","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.amjms.2022.07.008","volume":"365","author":"C-P Chun","year":"2023","unstructured":"Chun C-P, Song L-X, Zhang H-P, Guo D-D, Xu G-X, Li Y, Xin X, Cao J, Li F. Malignant peritoneal mesothelioma. Am J Med Sci. 2023;365:99\u2013103. https:\/\/doi.org\/10.1016\/j.amjms.2022.07.008.","journal-title":"Am J Med Sci"},{"key":"756_CR16","doi-asserted-by":"publisher","first-page":"129","DOI":"10.21037\/jovs.2016.07.12","volume":"2","author":"O Wald","year":"2016","unstructured":"Wald O, Groth SS, Burt BM, Sugarbaker DJ. Role of thoracoscopy, mediastinoscopy and laparoscopy in the diagnosis and staging of malignant pleural mesothelioma. J Vis Surg. 2016;2:129\u2013129. https:\/\/doi.org\/10.21037\/jovs.2016.07.12.","journal-title":"J Vis Surg"},{"key":"756_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2023.100557","volume":"4","author":"I Dagogo-Jack","year":"2023","unstructured":"Dagogo-Jack I, Yeap BY, Mino-Kenudson M, Digumarthy SR. Extrathoracic metastases in pleural mesothelioma. JTO Clin Res Rep. 2023;4: 100557. https:\/\/doi.org\/10.1016\/j.jtocrr.2023.100557.","journal-title":"JTO Clin Res Rep"},{"key":"756_CR18","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20220339","author":"C Owens","year":"2023","unstructured":"Owens C, Hindocha S, Lee R, Millard T, Sharma B. The lung cancers: staging and response, CT, 18 F-FDG PET\/CT, MRI, DWI: review and new perspectives. Br J Radiol. 2023. https:\/\/doi.org\/10.1259\/bjr.20220339.","journal-title":"Br J Radiol"},{"key":"756_CR19","doi-asserted-by":"publisher","first-page":"W215","DOI":"10.2214\/AJR.13.10572","volume":"201","author":"M Kruse","year":"2013","unstructured":"Kruse M, Sherry SJ, Paidpally V, Mercier G, Subramaniam RM. FDG PET\/CT in the management of primary pleural tumors and pleural metastases. Am J Roentgenol. 2013;201:W215\u201326. https:\/\/doi.org\/10.2214\/AJR.13.10572.","journal-title":"Am J Roentgenol"},{"key":"756_CR20","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40336-021-00445-w","volume":"9","author":"M Casali","year":"2021","unstructured":"Casali M, Lauri C, Altini C, Bertagna F, Cassarino G, Cistaro A, Erba AP, Ferrari C, Mainolfi CG, Palucci A, et al. State of the art of 18F-FDG PET\/CT application in inflammation and infection: a guide for image acquisition and interpretation. Clin Transl Imaging. 2021;9:299\u2013339. https:\/\/doi.org\/10.1007\/s40336-021-00445-w.","journal-title":"Clin Transl Imaging"},{"key":"756_CR21","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.lungcan.2015.07.015","volume":"90","author":"RJ Francis","year":"2015","unstructured":"Francis RJ, Segard T, Morandeau L, Lee YCG, Millward MJ, Segal A, Nowak AK. Characterization of hypoxia in malignant pleural mesothelioma with FMISO PET-CT. Lung Cancer. 2015;90:55\u201360. https:\/\/doi.org\/10.1016\/j.lungcan.2015.07.015.","journal-title":"Lung Cancer"},{"key":"756_CR22","doi-asserted-by":"publisher","first-page":"96732","DOI":"10.18632\/oncotarget.18235","volume":"8","author":"C Lapa","year":"2017","unstructured":"Lapa C, Kircher S, Schirbel A, Rosenwald A, Kropf S, Pelzer T, Walles T, Buck AK, Weber WA, Wester H-J, et al. Targeting CXCR4 with [68Ga]Pentixafor: a suitable theranostic approach in pleural mesothelioma? Oncotarget. 2017;8:96732\u20137. https:\/\/doi.org\/10.18632\/oncotarget.18235.","journal-title":"Oncotarget"},{"key":"756_CR23","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.3654","author":"K Kitajima","year":"2018","unstructured":"Kitajima K, Nakamichi T, Hasegawa S, Kuribayashi K, Yamakado K. Fluorodeoxyglucose versus choline positron emission tomography\/computed tomography response evaluation in two malignant pleural mesothelioma patients treated with talc pleurodesis and neoadjuvant chemotherapy. Cureus. 2018. https:\/\/doi.org\/10.7759\/cureus.3654.","journal-title":"Cureus"},{"key":"756_CR24","doi-asserted-by":"publisher","first-page":"e116","DOI":"10.1097\/RLU.0000000000002416","volume":"44","author":"M Rensi","year":"2019","unstructured":"Rensi M, Ferretti G, Di Gregorio F, Evangelista L. Pleural mesothelioma detects by 18F-choline PET\/CT in a patient with biochemical recurrence of prostate cancer. Clin Nucl Med. 2019;44:e116\u20137. https:\/\/doi.org\/10.1097\/RLU.0000000000002416.","journal-title":"Clin Nucl Med"},{"key":"756_CR25","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1097\/MNM.0000000000001078","volume":"40","author":"E Lopci","year":"2019","unstructured":"Lopci E, Novellis P, Testori A, Rahal D, Voulaz E, Bottoni E, Ferraroli GM, Crepaldi A, Ceresoli GL, Perrino M, et al. In-vivo imaging of methionine metabolism in patients with suspected malignant pleural mesothelioma. Nucl Med Commun. 2019;40:1179\u201386. https:\/\/doi.org\/10.1097\/MNM.0000000000001078.","journal-title":"Nucl Med Commun"},{"key":"756_CR26","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1007\/s00259-020-05132-y","volume":"48","author":"S Ballal","year":"2021","unstructured":"Ballal S, Yadav MP, Moon ES, Kramer VS, Roesch F, Kumari S, Tripathi M, ArunRaj ST, Sarswat S, Bal C. Biodistribution, pharmacokinetics, dosimetry of [68Ga]Ga-DOTA.SA.FAPi, and the head-to-head comparison with [18F]F-FDG PET\/CT in patients with various cancers. Eur J Nucl Med Mol Imaging. 2021;48:1915\u201331. https:\/\/doi.org\/10.1007\/s00259-020-05132-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"756_CR27","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.1097\/RLU.0000000000003858","volume":"47","author":"C G\u00fcndo\u011fan","year":"2022","unstructured":"G\u00fcndo\u011fan C, G\u00fczel Y, K\u00f6mek H, Etem H, Kaplan \u0130. 68Ga-FAPI-04 PET\/CT versus 18F-FDG PET\/CT in malignant peritoneal mesothelioma. Clin Nucl Med. 2022;47:e113\u20135. https:\/\/doi.org\/10.1097\/RLU.0000000000003858.","journal-title":"Clin Nucl Med"},{"key":"756_CR28","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1097\/RLU.0000000000004269","volume":"47","author":"A Dong","year":"2022","unstructured":"Dong A, Zhao B, Cheng C, Zuo C. 68Ga-FAPI-04 versus 18F-FDG PET\/CT in detection of epithelioid malignant pleural mesothelioma. Clin Nucl Med. 2022;47:980\u20131. https:\/\/doi.org\/10.1097\/RLU.0000000000004269.","journal-title":"Clin Nucl Med"},{"key":"756_CR29","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1097\/RLU.0000000000004575","volume":"48","author":"J Li","year":"2023","unstructured":"Li J, Yang J, Hu S. Malignant peritoneal mesothelioma with butterfly-shaped muscle metastasis. Clin Nucl Med. 2023;48:348\u201350. https:\/\/doi.org\/10.1097\/RLU.0000000000004575.","journal-title":"Clin Nucl Med"},{"key":"756_CR30","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1097\/MNM.0000000000001702","volume":"44","author":"Y G\u00fczel","year":"2023","unstructured":"G\u00fczel Y, K\u00f6mek H, Can C, Kaplan \u0130, Kepenek F, Ebin\u00e7 S, B\u00fcy\u00fckdeniz MP, G\u00fcndo\u011fan C, Oru\u00e7 Z. Comparison of the role of 18F-Fluorodeoxyglucose PET\/computed tomography and 68Ga-labeled FAP inhibitor-04 PET\/CT in patients with malignant mesothelioma. Nucl Med Commun. 2023;44:631\u20139. https:\/\/doi.org\/10.1097\/MNM.0000000000001702.","journal-title":"Nucl Med Commun"},{"key":"756_CR31","doi-asserted-by":"publisher","DOI":"10.1111\/1754-9485.13592","author":"IJ May","year":"2023","unstructured":"May IJ, Nowak AK, Francis RJ, Ebert MA, Dhaliwal SS. The prognostic value of F18 fluorothymidine positron emission tomography for assessing the response of malignant pleural mesothelioma to chemotherapy\u2014a prospective cohort study. J Med Imaging Radiat Oncol. 2023. https:\/\/doi.org\/10.1111\/1754-9485.13592.","journal-title":"J Med Imaging Radiat Oncol"},{"key":"756_CR32","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/RLU.0000000000005123","volume":"49","author":"F Kalantari","year":"2024","unstructured":"Kalantari F, Schweighofer-Zwink G, Rendl G, Pirich C, Beheshti M. 18F-FDG and 68Ga-PSMA PET\/CT in paratesticular mesothelioma. Clin Nucl Med. 2024;49:332\u2013332. https:\/\/doi.org\/10.1097\/RLU.0000000000005123.","journal-title":"Clin Nucl Med"},{"key":"756_CR33","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.2967\/jnumed.124.267473","volume":"65","author":"L Kessler","year":"2024","unstructured":"Kessler L, Schwaning F, Metzenmacher M, Pabst K, Siveke J, Trajkovic-Arsic M, Schaarschmidt B, Wiesweg M, Aigner C, Pl\u00f6nes T, et al. Fibroblast activation protein\u2013directed imaging outperforms 18F-FDG PET\/CT in malignant mesothelioma: a prospective, single-center, observational trial. J Nucl Med. 2024;65:1188\u201393. https:\/\/doi.org\/10.2967\/jnumed.124.267473.","journal-title":"J Nucl Med"},{"key":"756_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2022.100382","volume":"3","author":"TA Szyszko","year":"2022","unstructured":"Szyszko TA, Dunn JT, Phillips MM, Bomalaski J, Sheaff MT, Ellis S, Pike L, Goh V, Cook GJR, Szlosarek PW. Role of 3\u2019-Deoxy-3\u2019-[18F] fluorothymidine positron emission tomography-computed tomography as a predictive biomarker in argininosuccinate synthetase 1-deficient thoracic cancers treated with pegargiminase. JTO Clin Res Rep. 2022;3: 100382. https:\/\/doi.org\/10.1016\/j.jtocrr.2022.100382.","journal-title":"JTO Clin Res Rep"},{"key":"756_CR35","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1021\/acs.bioconjchem.0c00617","volume":"32","author":"P Kr\u0119cisz","year":"2021","unstructured":"Kr\u0119cisz P, Czarnecka K, Kr\u00f3licki L, Mikiciuk-Olasik E, Szyma\u0144ski P. Radiolabeled peptides and antibodies in medicine. Bioconjug Chem. 2021;32:25\u201342. https:\/\/doi.org\/10.1021\/acs.bioconjchem.0c00617.","journal-title":"Bioconjug Chem"},{"key":"756_CR36","doi-asserted-by":"publisher","first-page":"60581","DOI":"10.18632\/oncotarget.19943","volume":"8","author":"Y Qi","year":"2017","unstructured":"Qi Y, Liu X, Li J, Yao H, Yuan S. Fluorine-18 labeled amino acids for tumor PET\/CT imaging. Oncotarget. 2017;8:60581\u20138. https:\/\/doi.org\/10.18632\/oncotarget.19943.","journal-title":"Oncotarget"},{"key":"756_CR37","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.3390\/pharmaceutics14102207","volume":"14","author":"C Wang","year":"2022","unstructured":"Wang C, Lin R, Yao S. Recent advances in 18F-labeled amino acids synthesis and application. Pharmaceutics. 2022;14:2207. https:\/\/doi.org\/10.3390\/pharmaceutics14102207.","journal-title":"Pharmaceutics"},{"key":"756_CR38","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/j.ejca.2012.01.016","volume":"48","author":"K Kaira","year":"2012","unstructured":"Kaira K, Serizawa M, Koh Y, Takahashi T, Hanaoka H, Oriuchi N, Endo M, Kondo H, Nakajima T, Yamamoto N. Relationship between 18F-FDG uptake on positron emission tomography and molecular biology in malignant pleural mesothelioma. Eur J Cancer. 2012;48:1244\u201354. https:\/\/doi.org\/10.1016\/j.ejca.2012.01.016.","journal-title":"Eur J Cancer"},{"key":"756_CR39","doi-asserted-by":"publisher","first-page":"94969","DOI":"10.18632\/oncotarget.21662","volume":"8","author":"Z Xu","year":"2017","unstructured":"Xu Z, Li X-F, Zou H, Sun X, Shen B. 18F-Fluoromisonidazole in tumor hypoxia imaging. Oncotarget. 2017;8:94969\u201379. https:\/\/doi.org\/10.18632\/oncotarget.21662.","journal-title":"Oncotarget"},{"key":"756_CR40","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40644-020-00300-7","volume":"20","author":"F de Galiza Barbosa","year":"2020","unstructured":"de Galiza Barbosa F, Queiroz MA, Nunes RF, Costa LB, Zaniboni EC, Marin JFG, Cerri GG, Buchpiguel CA. Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings. Cancer Imaging. 2020;20:23. https:\/\/doi.org\/10.1186\/s40644-020-00300-7.","journal-title":"Cancer Imaging"},{"key":"756_CR41","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.ejca.2012.05.005","volume":"49","author":"UM Domanska","year":"2013","unstructured":"Domanska UM, Kruizinga RC, Nagengast WB, Timmer-Bosscha H, Huls G, de Vries EGE, Walenkamp AME. A review on CXCR4\/CXCL12 axis in oncology: no place to hide. Eur J Cancer. 2013;49:219\u201330. https:\/\/doi.org\/10.1016\/j.ejca.2012.05.005.","journal-title":"Eur J Cancer"},{"key":"756_CR42","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/prca.201300095","volume":"8","author":"EJ Hamson","year":"2014","unstructured":"Hamson EJ, Keane FM, Tholen S, Schilling O, Gorrell MD. Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy. Proteomics Clin Appl. 2014;8:454\u201363. https:\/\/doi.org\/10.1002\/prca.201300095.","journal-title":"Proteomics Clin Appl"},{"key":"756_CR43","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/path.2829","volume":"223","author":"T Li","year":"2011","unstructured":"Li T, Li H, Wang Y, Harvard C, Tan J-L, Au A, Xu Z, Jablons DM, You L. The expression of CXCR4, CXCL12 and CXCR7 in malignant pleural mesothelioma. J Pathol. 2011;223:519\u201330. https:\/\/doi.org\/10.1002\/path.2829.","journal-title":"J Pathol"},{"key":"756_CR44","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/1479-5876-11-187","volume":"11","author":"PC Schuberth","year":"2013","unstructured":"Schuberth PC, Hagedorn C, Jensen SM, Gulati P, van den Broek M, Mischo A, Soltermann A, J\u00fcngel A, Marroquin Belaunzaran O, Stahel R, et al. Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T Cells. J Transl Med. 2013;11:187. https:\/\/doi.org\/10.1186\/1479-5876-11-187.","journal-title":"J Transl Med"},{"key":"756_CR45","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1056\/NEJMc071823","volume":"357","author":"GL Ceresoli","year":"2007","unstructured":"Ceresoli GL, Chiti A, Santoro A. 11C-labeled methionine and evaluation of malignant pleural mesothelioma. N Engl J Med. 2007;357:1982\u20134. https:\/\/doi.org\/10.1056\/NEJMc071823.","journal-title":"N Engl J Med"},{"key":"756_CR46","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/RLU.0000000000002901","volume":"45","author":"E Kodama","year":"2020","unstructured":"Kodama E, Kodama T, Ichikawa T, Ikoma H, Hashimoto J. 18F-FDG uptake of localized malignant peritoneal mesothelioma. Clin Nucl Med. 2020;45:161\u20133. https:\/\/doi.org\/10.1097\/RLU.0000000000002901.","journal-title":"Clin Nucl Med"},{"key":"756_CR47","first-page":"603","volume":"47","author":"JM Engles","year":"2006","unstructured":"Engles JM, Quarless SA, Mambo E, Ishimori T, Cho SY, Wahl RL. Stunning and its effect on 3H-FDG uptake and key gene expression in breast cancer cells undergoing chemotherapy. J Nucl Med. 2006;47:603\u20138.","journal-title":"J Nucl Med"},{"key":"756_CR48","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/life13091821","volume":"2023","author":"P Guglielmo","year":"1821","unstructured":"Guglielmo P, Alongi P, Baratto L, Abenavoli E, Buschiazzo A, Celesti G, Conte M, Filice R, Gorica J, Jonghi-Lavarini L, et al. Head-to-head comparison of FDG and radiolabeled FAPI PET: a systematic review of the literature. Life. 1821;2023:13. https:\/\/doi.org\/10.3390\/life13091821.","journal-title":"Life"},{"key":"756_CR49","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2147\/ITT.S291767","volume":"10","author":"R Bughda","year":"2021","unstructured":"Bughda R, Dimou P, D\u2019Souza RR, Klampatsa A. Fibroblast activation protein (FAP)-targeted CAR-T cells: launching an attack on tumor stroma. Immunotargets Ther. 2021;10:313\u201323. https:\/\/doi.org\/10.2147\/ITT.S291767.","journal-title":"Immunotargets Ther"},{"key":"756_CR50","doi-asserted-by":"publisher","first-page":"192","DOI":"10.33696\/immunology.2.042","volume":"2","author":"A Klampatsa","year":"2020","unstructured":"Klampatsa A, Albelda SM. Current advances in CAR T cell therapy for malignant mesothelioma. J Cell Immunol. 2020;2:192\u2013200. https:\/\/doi.org\/10.33696\/immunology.2.042.","journal-title":"J Cell Immunol"},{"key":"756_CR51","doi-asserted-by":"publisher","first-page":"4346","DOI":"10.1158\/1078-0432.CCR-22-1432","volume":"28","author":"WP Fendler","year":"2022","unstructured":"Fendler WP, Pabst KM, Kessler L, Fragoso Costa P, Ferdinandus J, Weber M, Lippert M, Lueckerath K, Umutlu L, Kostbade K, et al. Safety and efficacy of 90Y-FAPI-46 radioligand therapy in patients with advanced sarcoma and other cancer entities. Clin Cancer Res. 2022;28:4346\u201353. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-1432.","journal-title":"Clin Cancer Res"},{"key":"756_CR52","doi-asserted-by":"publisher","first-page":"839","DOI":"10.3390\/cancers16040839","volume":"16","author":"P Guglielmo","year":"2024","unstructured":"Guglielmo P, Alongi P, Baratto L, Conte M, Abenavoli EM, Buschiazzo A, Celesti G, Dondi F, Filice R, Gorica J, et al. FAPi-based agents in thyroid cancer: a new step towards diagnosis and therapy? A systematic review of the literature. Cancers (Basel). 2024;16:839. https:\/\/doi.org\/10.3390\/cancers16040839.","journal-title":"Cancers (Basel)"},{"key":"756_CR53","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1007\/s00259-023-06144-0","volume":"50","author":"BM Priv\u00e9","year":"2023","unstructured":"Priv\u00e9 BM, Boussihmad MA, Timmermans B, van Gemert WA, Peters SMB, Derks YHW, van Lith SAM, Mehra N, Nagarajah J, Heskamp S, et al. fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies. Eur J Nucl Med Mol Imaging. 2023;50:1906\u201318. https:\/\/doi.org\/10.1007\/s00259-023-06144-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"756_CR54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0018198","volume":"6","author":"TK Nayak","year":"2011","unstructured":"Nayak TK, Garmestani K, Milenic DE, Baidoo KE, Brechbiel MW. HER1-targeted 86Y-panitumumab possesses superior targeting characteristics than 86Y-cetuximab for PET imaging of human malignant mesothelioma tumors xenografts. PLoS ONE. 2011;6(3): e18198.","journal-title":"PLoS ONE"},{"key":"756_CR55","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.3390\/molecules23123138","volume":"23","author":"V Izquierdo-S\u00e1nchez","year":"2018","unstructured":"Izquierdo-S\u00e1nchez V, Mu\u00f1iz-Hern\u00e1ndez S, V\u00e1zquez-Becerra H, Pacheco-Yepez J, Romero-Pi\u00f1a ME, Arrieta O, Medina LA. Biodistribution and tumor uptake of 67Ga-nimotuzumab in a malignant pleural mesothelioma xenograft. Molecules. 2018;23:3138. https:\/\/doi.org\/10.3390\/molecules23123138.","journal-title":"Molecules"}],"container-title":["Molecular Diagnosis &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-024-00756-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40291-024-00756-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-024-00756-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T07:49:53Z","timestamp":1737100193000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40291-024-00756-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,8]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["756"],"URL":"https:\/\/doi.org\/10.1007\/s40291-024-00756-4","relation":{},"ISSN":["1177-1062","1179-2000"],"issn-type":[{"value":"1177-1062","type":"print"},{"value":"1179-2000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,8]]},"assertion":[{"value":"28 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors (P.G., C.C., A.C., C.M.D.C., M.P., S.M., M.O., P.A.Z., and L.E.) declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"Institutional review board approval was not required, because the paper is a review.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval:"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publication"}},{"value":"Priscilla Guglielmo (data acquisition, analysis, or interpretation; intellectual content development or critical review; and final version approval), Cinzia Crivellaro (data acquisition, analysis, or interpretation; intellectual content development or critical review; and final version approval), Angelo Castello (data acquisition, analysis, or interpretation; intellectual content development or critical review; and final version approval), Carminia Maria Della Corte (data acquisition, analysis, or interpretation; intellectual content development or critical review; and final version approval), Maria Pagano (data acquisition, analysis, or interpretation; intellectual content development or critical review; and final version approval), Silvia Marchesi (data acquisition, analysis, or interpretation; intellectual content development or critical review; and final version approval), Mario Occhipinti (intellectual content development, or critical review; final version approval; and integrity), Paolo Andrea Zucali (intellectual content development, or critical review; final version approval; and integrity), Laura Evangelista (conception or design; data acquisition, analysis, or interpretation; intellectual content development or critical review; final version approval; and integrity).","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}